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Background: Type 2 diabetes mellitus (T2DM) is independently associated with an increased risk for cardiovascular
diseases that is primarily due to the early development of advanced atherosclerotic vascular changes. The aim of our
study was to investigate the predictors of vascular dysfunction in T2DM patients.
Methods: We studied 165 T2DM patients without known macrovascular or microvascular disease. Standard demographic
(age, gender, cardiovascular risk factors, medications), clinical (body mass index, blood pressure) and laboratory (glucose,
glycated hemoglobin, lipids, renal function) parameters were included in analyses. Brachial artery flow-mediated dilation
(FMD), nitrate mediated dilation (NMD) and Carotid-Femoral Pulse Wave Velocity (PWV)
were measured.
Results: Median age was 66 years and duration since T2DM diagnosis was 10 years, 70% were females and 79%
hypertensives, while only 10% had a glycated hemoglobin <7%. FMD was positively associated with NMD (r 0.391, P <
0.001), while PWV was inversely associated with FMD (r -0.218, P = 0.014) and NMD (r -0.309, P < 0.001). Time since
diagnosis of diabetes was the single independent predictor of FMD (β -0.40, P = 0.003). Increased age and fasting glucose
and the presence of hypertension were independent predictors of decreased NMD (P < 0.001). Increased age and systolic
blood pressure were independently associated with increased PWV (P < 0.001).
Conclusions: In T2DM patients, impairment of endothelium-dependent vasodilation was independently associated only
with longer diabetes duration while no association with other established risk factors was found. Vascular smooth muscle
dysfunction and increased arterial stiffness were more prominent in older T2DM patients with hypertension. Worse
glycemic control was associated with impaired vascular smooth muscle function.
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AtherosclerosisBackground
Type 2 diabetes mellitus (T2DM) is independently asso-
ciated with an increased risk for cardiovascular diseases
(CVD) [1] that is primarily due to the early development
of advanced atherosclerotic vascular changes [2]. Vascu-
lar endothelial and smooth muscle cell dysfunction as
well as large arterial stiffness are considered to be mar-
kers of subclinical atherosclerosis with a significant
prognostic role in high risk populations [3-10]. Endothe-
lial dysfunction, as assessed by decreased endothelium-* Correspondence: lmihalis@cc.uoi.gr
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reproduction in any medium, provided the ordependent flow-mediated dilation (FMD) of the brachial
artery [11-19], and increased arterial stiffness, assessed
by aortic pulse wave velocity (PWV) [7,20-22], have been
previously demonstrated in patients with T2DM com-
pared to controls. Whether vascular smooth muscle cell
function, assessed by nitrate mediated dilation (NMD) of
the brachial artery [11-13,15,16,18,23] is also affected in
T2DM patients has been questioned in previous studies.
The mechanisms underlying the association of T2DM
with vascular dysfunction are considered to be complex.
Classical cardiovascular risk factors (hypertension, dyslipi-
demia and smoking) may play a role, while diabetes-related
parameters such as hyperglycemia, insulin resistance and
obesity, and other associated emerging risk factors such asd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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terial function indices in T2DM. The relative importance of
these risk factors in the induction of vascular dysfunction
in T2DM patients has not been well studied previously.
The aim of our study was to investigate the predictors
of vascular function, as assessed by brachial artery FMD
and NMD and carotid-femoral PWV in T2DM patients
without known macrovascular or microvascular disease.
Methods
Subjects
A total of 165 patients with previously diagnosed type 2
diabetes mellitus were consecutively recruited from the
Endocrinology outpatient clinics of the University Hos-
pital and Hatzikosta General Hospital of Ioannina, Ioan-
nina, Greece from 2007 to 2009. Diagnosis of type 2
diabetes mellitus was defined according to the American
Diabetes Association and the European Association for
the Study of Diabetes [24]. Eligible subjects were
patients 40 – 80 years old, under stable treatment with
oral antidiabetic medications (metformin, sulfonylureas)
or/and insulin for at least 6 months prior to study en-
rollment. No patient was on thiazolidinedione therapy.
The duration of diabetes was defined as time since
T2DM diagnosis and was confirmed by the patients’
clinical records. Patients reporting a history of macro-
vascular disease (coronary artery, cerebrovascular, or
peripheral vascular disease), microvascular disease (dia-
betic retinopathy, symptomatic neuropathy, proteinuria),
chronic heart failure, liver disease (or abnormal liver
enzymes at study entry), anemia, thyroid dysfunction or
other endocrine diseases and alcoholism were excluded
from the study.
The study was approved by the Ethics Committee of
the Michaelidion Cardiac Center, University of Ioannina,
Greece and informed consent was obtained from all
patients. The study complies with the Declaration of
Helsinki.
Risk factor assessment
All participants underwent a medical interview con-
cerning disease and risk factor history and general use
of medications. A physical examination was then per-
formed including measurement of blood pressure,
height and weight. Office blood pressure (BP) was
measured in the sitting position after 5 min of rest
(just before the assessment of arterial stiffness indices)
using an automated brachial sphygmomanometer
(Omron M7, Omron Healthcare Co, Kyoto, Japan),
and the mean of three consecutive measurements by a
trained operator was reported. Body mass index (BMI)
was calculated as weight/height2 (kg/m2). The follow-
ing definitions were used: hypertension; blood pressure
(BP) >140/90 mmHg or use of any antihypertensivemedications, hypercholesterolemia; low density lipopro-
tein cholesterol (LDL-c) >2.6 mmol/l (100 mg/dl) or
use of lipid-lowering agents (statins). Patients who
were smoking at the time of study or had stopped
smoking during the last 12 months prior to the study
were defined as current smokers.
Laboratory investigations
Serum fasting glucose was determined by the hexoki-
nase method and HbA1C by a latex agglutination inhib-
ition assay (Randox, UK). Serum total and high density
lipoprotein (HDL-c) cholesterol and triglycerides were
measured by an enzymatic colorimetric assay. All assays
were performed using an Olympus 640 analyser (Olym-
pus Diagnostica GmbH, Hamburg, Germany). LDL-c
was calculated using the Friedewald formula: LDL-c =
total cholesterol - HDL-c - (triglycerides/5). Serum and
urine creatinine concentrations were measured using an
enzymatic method. Urinary albumin was measured by a
turbidimetric assay. Subsequently, urinary albumin ex-
cretion was evaluated by assessment of urine albumin-
to-creatinine ratio in a spot sample. Microalbuminuria
was defined as urine albumin-to-creatinine ratio be-
tween 3.5 – 35 mg/mmol creatinine for at least 2 out
of 3 consecutive measurements. The glomerular filtra-
tion rate (GFR) was calculated using the chronic kidney
disease epidemiology collaboration (CKD-EPI) formula
(ml/min/1.73 m2) [25]. Serum high sensitivity C-reactive
protein (hs-CRP) was measured using rate turbidimetry
(IMMAGE Immunochemistry Systems and Calibrator 5
Plus, Beckman Coulter Inc, Fullerton, CA, USA).
Vascular measurements
All vascular studies were performed early in the morning
with the subjects fasted and refrained from smoking for
at least 14 h before the study. All measurements were
taken in the supine position in a quiet, temperature con-
trolled room (~22°C) after a 30-min period of rest. All
studies were performed by the same operator who was
unaware of the patient’s medical history.
Assessment of endothelial and smooth muscle cell function
in the brachial artery
Endothelial function was assessed by measurement of
endothelium-dependent flow-mediated dilation (FMD)
in the right brachial artery in response to hand hyper-
aemia. FMD was measured as previously described [26]
according to published guidelines [27]. Images of the
brachial artery were acquired at baseline, during hand
hyperaemia at 90 sec after deflation of a wrist cuff
inflated to 300 mmHg for 5 min for measurement of
FMD, and at 4 min after 400 μg of sublingual glyceryl
trinitrate for measurement of endothelium-independent,
nitrate-mediated vasodilatation (NMD). FMD and NMD
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ing hyperaemia and after nitrate administration respect-
ively compared with the diameter at rest. Brachial artery
blood flow was measured by continuous wave Doppler
at rest and at 15 seconds after cuff release. An Echo-
Doppler ultrasound system (Ultrasound ATL, HDI 5000,
Bophell, WA, USA) and a 5–12 MHz transducer were
used for optimal imaging of the brachial artery. Images
were recorded on super-VHS videotape (VCR Panasonic
AG-MD 835, Osaka, Japan) for off-line analysis. Meas-
urement of brachial artery diameter was performed by
another blinded operator, at end-diastole coincident with
the R-wave on the electrocardiogram, using electronic
calipers from the anterior to the posterior m-line at a
fixed distance from an anatomic marker. Internal repeat-
ability data of FMD and NMD measurements in our
laboratory have been previously published [26].
Assessment of arterial stiffness
Arterial stiffness was assessed non-invasively with the
commercially available Sphygmocor system (Version
7.01, At Cor Medical, Sydney, Australia) using applana-
tion tonometry to measure carotid-femoral pulse wave
velocity (PWV) as previously described [28]. Pressure
waveforms were recorded from the carotid and femoral
arteries. The distance travelled by the pulse wave was
measured over the body surface as the distance between
the two recording sites, and the distance from the
suprasternal notch to the carotid was subtracted. Wave
transit time (t) between the recording sites was calcu-
lated by the system software, using the R wave on the
simultaneously recorded electrocardiogram as reference
frame. PWV was calculated as distance/transit time. In
studies performed on two separate days (8–12 days
apart) in 12 subjects by a single operator, the within-
subject coefficient of variation of PWV was 5.6%.
Statistical analysis
Continuous variables are presented as mean ± SD and
categorical variables are shown as number (percentage,
%). Kolmogorov–Smirnov Z-test was used to determine
the normal distribution of continuous variables; age, dia-
betes duration and hs-CRP were not normally distribu-
ted. For not normally distributed variables data are
presented as median (range). Univariate associations be-
tween FMD, NMD, PWV and other studied continuous
variables were assessed using Pearson’s and Spearman’s
correlation coefficients. For the categorical variables, dif-
ferences in vascular indices were tested using the un-
paired t-test. Subsequently, variables whose association
with the vascular parameters achieved statistical signifi-
cance (i.e. P < 0.05) as well as other factors that may
affect endothelial dysfunction and arterial stiffness (age,
gender, heart rate, systolic blood pressure and use ofantihypertensive medications) were entered into a step-
wise linear regression model to determine independent
predictors of vascular parameters. Variables not nor-
mally distributed were logarithmically transformed in
order to be used in univariate and multivariate associ-
ation analysis. A P value of <0.05 was considered signifi-
cant. The observed power for the multiple regression
analysis given the observed probability level (<0.05), the
number of predictors, the observed R2 and the sample
size, was approximately 85% for FMD and 99% for both
NMD and PWV. The SPSS statistical software package
(version 15.0 for Windows, SPSS Inc. Chicago, IL, USA)
was used.
Results
Characteristics of subjects with T2DM are presented in
Table 1. Median age of our population was 66 years and
median time since the diagnosis of diabetes was 10 years.
Most of our patients were females (70%), hypertensives
(79%) and hypercholesterolemic (91%) with suboptimal
control of systolic blood pressure (146±15 mmHg i.e.
68% had systolic blood pressure >140 mmHg and only
5% had diastolic blood pressure >90 mmHg) and LDL-c
(3.4±0.9 mmol/L, i.e. 82% had an LDL-c >2.6 mmol/L),
while 46% of the total population were obese (BMI
>30 kg/m2). Good glycaemic control (HbA1c <7%) was
observed in 10% of our patients.
In our population, FMD was positively associated
with NMD (r 0.391, P < 0.001), while PWV was in-
versely associated with FMD (r −0.218, P = 0.014) and
NMD (r −0.309, P < 0.001).
The associations between the vascular indices and
other studied parameters are shown in Table 2 (continu-
ous variables) and Table 3 (categorical variables). In
multivariate analysis (Table 4), increased duration of dia-
betes was found to be the single independent predictor
of decreased FMD (R2 0.05, P = 0.003), while increased
age and fasting glucose as well as the presence of hyper-
tension were independent predictors of decreased NMD
(R2 0.16, P < 0.001). Increased age and SBP were inde-
pendently associated with increased PWV (R2 0.25, P <
0.001) (Table 4).
Discussion
In the current study in T2DM patients, indices of vascu-
lar function were found to be inter-related suggesting
that they probably reflect overlapping pathophysiological
aspects of the vascular atherosclerotic damage in T2DM
patients. Further to this finding, markers of endothelial
function (FMD), smooth muscle cell function (NMD)
and large artery stiffness (PWV) were shown to share
common correlates. Older age, longer duration of dia-
betes and treatment with insulin were associated with all
markers of vascular dysfunction, although each marker
Table 1 Characteristics of the studied population
(n = 165)
Demographics
Age, years 66 (40, 80)
Female gender, n (%) 116 (70)
Time since diagnosis of diabetes, years 10 (1, 33)
Smoking, n (%) 28 (17)
Hypertension, n (%) 131 (79)
Antihypertensive medications, n (%) 109 (66)
ACE-I/ARBs 84 (51)
Calcium channel blockers 58 (35)
Diuretics 24 (15)
Beta blockers 13 (8)
Hypercholesterolemia, n (%) 150 (91)
Statins, n (%) 48 (29)
Oral antidiabetic medication, n (%) 129 (78)
Sulfonylureas 98 (59)
Metformin 89 (54)
Insulin treatment, n (%) 36 (22)
Body mass index, kg/m2 30.1 ± 5.5
Laboratory investigations
Fasting glucose, mmoL/L 9.4 ± 2.7
HbA1c, % 8.3 ± 1.2
Total cholesterol, mmoL/L 5.6 ± 1.0
HDL-c, mmoL/L 1.3 ± 0.3
Triglycerides, mmoL/L 1.7 ± 0.8
LDL-c, mmoL/L 3.4 ± 0.9
Creatinine, μmoL/L 78.7 ± 17.7
Glomerular filtration rate, ml/min/1.73 m2 78.1 ± 16.3
High sensitivity C-reactive protein, mg/l 1.84 (0.31, 9.71)
Albumin to Creatinine ratio, mg/mmol 1.20 (0.18, 34.50)
Microalbuminuria, n (%) 31 (19)
Vascular measurements
Heart rate, beats/min 72 ± 11
Systolic blood pressure, mmHg 146 ± 15
Diastolic blood pressure, mmHg 78 ± 7
Flow-mediated dilation, % 1.98 ± 1.66
Nitrate-mediated dilation, % 10.09 ± 3.84
Carotid-femoral pulse wave velocity, m/sec 10.2 ± 2.2
Continuous data are presented as mean ± SD. For not normally distributed
variables (age, time since diagnosis of diabetes, high sensitivity C-reactive
protein and urine albumin to creatinine ratio) data are presented as median
(range). ACE-I, angiotensin converting enzyme inhibitors; ARBs, angiotensin
receptor blockers; HbA1c, glycated hemoglobin; HDL-c, high density
lipoprotein cholesterol; LDL-c, low density lipoprotein cholesterol.
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distinct parameters.
Previous studies comparing patients with T2DM to
healthy controls have shown that T2DM is an independ-
ent risk factor for endothelial dysfunction [14,16,17].
The greater cardiovascular mortality risk observed inT2DM patients has been mainly attributed to vascular
endothelial dysfunction [17]. In T2DM patients without
macrovascular or microvascular disease, we found that
endothelial dysfunction, as assessed by reduced brachial
artery FMD, was independently associated only with
the duration of diabetes; for every 10 years of diabetes,
FMD is reduced by approximately 1.0% (in absolute
FMD values). Previous studies have shown significant
associations of FMD with diabetes duration [29,30] al-
though not consistently [31]. Longer T2DM duration
has also been shown to increase CVD risk and total
mortality significantly even after adjustment for estab-
lished and novel cardiovascular risk factors [32] sug-
gesting that there might be a link between T2DM
duration, worsening endothelial function and cardiovas-
cular prognosis in these patients. Furthermore, we
showed that impairment of endothelial function in
T2DM patients was not related to the presence or
levels of various established cardiovascular risk factors,
vascular inflammation or glycemic control. In accord-
ance with our findings previously reported data have
not shown an association of glycemic control with
endothelial dysfunction [31,33]. On the other hand,
endothelial dysfunction has been previously related to
the presence and levels of cardiovascular risk factors in
T2DM patients [23,29,30], although not consistently
[34], while vascular inflammation has been suggested
to play a central role in the development of endothelial
dysfunction [35]. It should be noted that compared to
other reports [23,29,30], our study included T2DM
patients with severely impaired FMD (mean FMD
1.98%) and a high prevalence of accumulated cardio-
vascular risk factors; in these patients longer duration
of diabetes, and not other established cardiovascular
risk factors, was the only important determinant of
endothelial dysfunction. Diabetes duration may appear
to be a more important contributor to endothelial dys-
function compared to indices of short-term glycaemic
control or other isolated risk factors as it may reflect
the total exposure of the endothelium to diabetes and
hyperglycaemia (metabolic memory) [36] as well as
other diabetes-related comorbidities (hypertension, dys-
lipidemia, obesity).
Vascular smooth muscle cell dysfunction has been
previously shown in T2DM patients compared to
healthy controls in addition to endothelial dysfunction
[11,13,15,37] indicating that T2DM may both reduce
the bioavailability of endothelial nitric oxide and at-
tenuate smooth muscle cells’ sensitivity to nitric oxide;
these findings have not been consistently replicated in
all studies [12,16,18,23]. Vascular smooth muscle cell
dysfunction has been previously reported in popula-
tions at high cardiovascular risk [38,39] and a prognos-
tic role has been suggested in such individuals [4,10].
Table 2 Associations between vascular measurements (FMD, NMD and PWV) and other continuous parameters in
univariate analysis
FMD, % NMD, % PWV, m/sec
r P r P r P
*Age, years −0.155 0.047 −0.319 <0.001 0.465 <0.001
*Time since diagnosis of diabetes, years −0.254 0.001 −0.272 <0.001 0.254 0.004
Body mass index, kg/m2 0.102 0.194 0.027 0.732 −0.217 0.015
Fasting glucose, mmoL/L −0.124 0.113 −0.196 0.011 0.024 0.793
HbA1c, % −0.117 0.135 −0.140 0.072 0.150 0.094
Total cholesterol, mmoL/L −0.058 0.459 0.082 0.297 −0.131 0.142
HDL-c, mmoL/L −0.101 0.197 −0.005 0.952 −0.053 0.555
Triglycerides, mmoL/L 0.028 0.724 0.066 0.397 0.034 0.702
LDL-c, mmoL/L −0.041 0.597 0.068 0.386 −0.143 0.110
Glomerular filtration rate, ml/min/1.73 m2 0.073 0.351 0.209 0.007 −0.274 0.002
*Albumin to Creatinine ratio, mg/mmol −0.052 0.607 0.025 0.808 −0.013 0.907
*High sensitivity C-reactive protein, mg/l 0.021 0.807 −0.121 0.161 0.057 0.556
Heart rate, beats/min −0.014 0.856 −0.067 0.393 0.089 0.323
Systolic blood pressure, mmHg −0.121 0.122 −0.231 0.003 0.305 0.001
Diastolic blood pressure, mmHg 0.022 0.777 −0.011 0.889 0.014 0.879
*Natural logarithm transformed variables. FMD, flow-mediated dilation of the brachial artery; HbA1c, glycated hemoglobin; HDL-c, high density lipoprotein
cholesterol; LDL-c, low density lipoprotein cholesterol; NMD, nitrate-mediated dilation of the brachial artery; PWV, carotid-femoral pulse wave velocity.
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ciated with older age, the presence of hypertension
and higher fasting glucose. Several previous studies
have not shown any significant associations of NMDTable 3 Associations of vascular measurements (FMD, NMD a
FMD, % P NMD
Gender
Male, n = 49 1.92 ± 1.56 10.32
Female, n = 116 2.00 ± 1.71 0.772 9.99
Smoking
Yes, n = 28 2.01 ± 1.47 10.33
No, n = 137 1.97 ± 1.70 0.900 10.04
Hypertension
Yes, n = 131 1.93 ± 1.65 9.58
No, n = 34 2.14 ± 1.73 0.528 12.05
Antihypertensive medications
Yes, n = 109 1.84 ± 1.64 9.09
No, n = 56 2.24 ± 1.68 0.143 12.03
Hypercholesterolemia
Yes, n = 150 1.94 ± 1.65 10.03
No, n = 15 2.29 ± 1.77 0.441 10.63
Statins
Yes, n = 48 1.99 ± 1.65 9.88
No, n = 117 1.97 ± 1.67 0.951 10.17
Insulin treatment
Yes, n = 36 1.53 ± 1.66 8.65
No, n = 129 2.10 ± 1.65 0.066 10.49
FMD, flow-mediated dilation of the brachial artery; NMD, nitrate-mediated dilation owith risk factors, glycemic control, inflammation or
other diabetes-related factors in T2DM patients
[13,31]. In agreement with our findings, hyperglycemia
was recently reported to be an independent predictornd PWV) with categorical parameters
, % P PWV, m/sec P
± 4.52 10.62 ± 2.54
± 3.51 0.648 10.02 ± 2.09 0.181
± 4.07 10.31 ± 2.58
± 3.80 0.720 10.16 ± 2.18 0.793
± 3.58 10.47 ± 2.24
± 4.19 0.001 9.25 ± 1.98 0.009
± 3.33 10.54 ± 2.12
± 4.05 <0.001 9.57 ± 2.31 0.019
± 3.86 10.19 ± 2.24
± 3.66 0.565 10.11 ± 2.23 0.911
± 3.91 10.57 ± 2.45
± 3.82 0.656 10.01 ± 2.12 0.199
± 3.01 11.12 ± 2.72
± 3.95 0.004 9.97 ± 2.06 0.059
f the brachial artery; PWV, carotid-femoral pulse wave velocity.
Table 4 Determinants of vascular measurements (FMD,
NMD and PWV) in multivariate analysis
Multivariate analysis
B (95% CI) P
FMD, % Time since diagnosis
of diabetes, years*
−0.40 (−0.66, -0.14) 0.003
NMD, % Age, years* −5.66 (−9.49, -1.82) 0.004
Hypertension −1.80 (−3.25, -0.35) 0.015
Fasting glucose, μmol/L −0.36 (−0.54, -0.18) 0.005
PWV, m/sec Age, years* 6.22 (3.81, 8.63) <0.001
Systolic blood pressure,
mmHg
0.03 (0.00, 0.05) 0.032
*Natural logarithm transformed variables. FMD, flow-mediated dilation of the
brachial artery; NMD, nitrate-mediated dilation of the brachial artery; PWV,
carotid-femoral pulse wave velocity.
The independent variables included in the stepwise model were parameters
whose association with the vascular parameters achieved statistical
significance (P < 0.05) and other factors that may affect endothelial
dysfunction and arterial stiffness (age, gender, heart rate, systolic blood
pressure and use of antihypertensive medications).
Naka et al. Cardiovascular Diabetology 2012, 11:127 Page 6 of 8
http://www.cardiab.com/content/11/1/127of impaired NMD in T1DM patients [40]. Hypergly-
cemia, by increasing advanced glycation end-products
and oxidative stress in the vascular wall, may be asso-
ciated with a decreased response of vascular smooth
muscle cells [15,35].
Arterial stiffness, as assessed by PWV, has been found to
be increased both in prediabetes [41] and in T2DM
patients compared to healthy controls [7,20-22]. Increased
PWV has been associated with a worse cardiovascular
prognosis in high risk patients [3,5,6] including T2DM
patients [7,9]. In the present study, increased PWV in
T2DM patients was independently associated with older
age and higher systolic blood pressure values confirming
well established knowledge. Both age and blood pressure
are considered to be the two most important determinants
of PWV in the general population [42] as well as in
T2DM patients [9,21]. In contrast to previous studies we
found no association of PWV with glycemic control in
T2DM patients [9,21,43,44]. Furthermore, although in-
flammation, as assessed by hs-CRP, has been suggested to
related to increased PWV in healthy subjects [45] as well
as in hypertensive [46] and T2DM [47] patients, this has
not been replicated in our study.
Our population consisted of patients with T2DM with
moderate glycaemic control and less than optimal con-
trol of other cardiovascular risk factors (blood pressure,
cholesterol, obesity). These results cannot be extrapo-
lated to all patients with T2DM; it is possible that includ-
ing patients with optimal control of risk factors,
important associations of risk factors with vascular indi-
ces may be revealed. Finally, whether interventions to
improve these risk factors may have a beneficial effect on
vascular indices has not been clarified in recent studies
[34,48,49], and cannot be precluded from this study.Study limitations
This was an observational study that could not reveal
causal relationships. Furthermore, regression models in
our study could predict a small part of the variability of
vascular indices (5–25%) in our population indicating
that other factors, not currently studied (e.g. insulin re-
sistance, advanced glycation end-products, genetic fac-
tors) may play a more important role in vascular
dysfunction in T2DM. Common insulin resistance/sensi-
tivity indices were not assessed because a high propor-
tion of the studied patients were receiving exogenous
insulin.Conclusion
In conclusion, in T2DM patients without known macro-
vascular or microvascular disease, impairment of
endothelium-dependent vasodilation was independently
associated only with longer diabetes duration while no
association with other established risk factors known to
be related to endothelial function was found. On the other
hand, vascular smooth cell dysfunction and increased ar-
terial stiffness were more prominent in older T2DM
patients with hypertension. Worse glycemic control was
only associated with impaired vascular smooth muscle cell
function. Further studies are needed to investigate the
clinical and prognostic implications of our findings.
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